Ultragenyx UK

Melphalan (ALKERAN) is an oral antineoplastic and immunomodulating small-molecule agent developed by Ultragenyx UK Limited for the treatment of amyloidosis. The program, identified by internal code 199/15927, completed Phase 2 clinical development with a latest milestone recorded on 9 June 2008. Melphalan is an established chemotherapeutic agent with a long regulatory history; it is approved in Australia (since 1 August 1991 under Aspen Pharmacare Australia), the European Union (authorised 22 May 2025 under ADIENNE S.r.l.), and the United States (with multiple generic sponsors including Alvogen and Apotex). The drug is administered orally and belongs to the antineoplastic and immunomodulating agents therapeutic class (ATC L01). Ultragenyx's amyloidosis program represents a repurposing strategy for an established chemotherapy backbone. The program's Phase 2 completion status and lack of disclosed subsequent milestones suggest the development pathway may have concluded or transitioned to a different strategic focus. Regulatory approvals across major markets confirm the drug's established safety and manufacturing profile, though specific efficacy and safety data in amyloidosis from the Phase 2 trial remain not yet disclosed in the available facts.

Amyloidosis represents a significant unmet medical need, particularly in systemic forms where protein misfolding leads to organ dysfunction and high mortality if untreated. The disease encompasses multiple subtypes (AL, AA, hereditary transthyretin, and others), each with distinct pathophysiology and treatment requirements. Melphalan has historical use in amyloidosis management, particularly in AL amyloidosis where it has been combined with autologous stem cell transplantation. Ultragenyx's Phase 2 program suggests an effort to establish or expand the evidence base for melphalan monotherapy or in a refined patient population within amyloidosis. The competitive landscape includes agents such as Kyprolis (carfilzomib, Amgen), which targets proteasome inhibition in plasma cell dyscrasias, and other immunomodulatory approaches. The commercial significance of amyloidosis therapeutics has grown substantially with emerging targeted therapies; however, the market remains relatively small due to disease rarity and diagnostic challenges. Melphalan's oral route of administration and established safety profile offer practical advantages over intravenous alternatives. The program's completion without disclosed advancement to Phase 3 or regulatory filing may reflect either negative efficacy signals, commercial deprioritisation, or transition to alternative development strategies. Understanding the Phase 2 outcomes is critical for assessing whether melphalan remains a viable monotherapy option or whether combination approaches are preferred in current amyloidosis treatment paradigms.

Drug Class: Antineoplastic and immunomodulating agent (ATC L01)

Modality: Small-molecule

Route of Administration: Oral

Brand Name: ALKERAN

International Nonproprietary Name (INN): Melphalan

Mechanism of Action: Not yet disclosed in available facts

Molecular Target: Not yet disclosed in available facts

Related Therapies: Melphalan is a nitrogen mustard alkylating agent historically used in multiple myeloma, light-chain amyloidosis (AL amyloidosis), and other plasma cell dyscrasias. Competitive agents in amyloidosis include proteasome inhibitors (e.g., Kyprolis—carfilzomib), immunomodulatory drugs (IMiDs), and emerging targeted therapies. The drug has been used in combination with autologous stem cell transplantation (ASCT) in AL amyloidosis treatment protocols.

First Approval: Australia, 1 August 1991 (Aspen Pharmacare Australia Pty Limited)

Patent Status: Not yet disclosed

• Approved in Australia (PBS code 2547C)
• Approved in European Union (EMA product number EMEA/H/C/005173, authorised 22 May 2025 under ADIENNE S.r.l.)
• Approved in United States (NDA014691 and ANDA207809 with sponsors Alvogen and Apotex)

United States: Melphalan is approved via NDA014691 and ANDA207809 with sponsors Alvogen and Apotex, indicating both innovator and generic approvals.

European Union: Melphalan (ALKERAN) is approved under EMA product number EMEA/H/C/005173, with marketing authorisation holder ADIENNE S.r.l., authorised 22 May 2025.

Australia: Melphalan is approved and listed on the Pharmaceutical Benefits Scheme (PBS) with code 2547C, sponsored by Aspen Pharmacare Australia Pty Limited, first listed 1 August 1991.

Japan (PMDA): Regulatory status not yet disclosed.

China (NMPA): Regulatory status not yet disclosed.

Patent Status: Not yet disclosed.

Expected Loss of Exclusivity: Not yet disclosed.

Melphalan's established approval across major markets reflects its long clinical history and established safety profile. The Ultragenyx-sponsored Phase 2 program in amyloidosis represents a development initiative for a specific indication rather than a novel drug entity approval pathway.

Strategic Implications: Ultragenyx's Phase 2 program in amyloidosis represents a repurposing strategy for an established chemotherapy agent. The program's completion in 2008 without disclosed advancement to Phase 3 or regulatory filing suggests either negative efficacy findings, commercial deprioritisation, or strategic pivot. The lack of subsequent milestones over 16+ years indicates the program may have been discontinued or placed on indefinite hold.

Competitive Positioning: Melphalan competes in a landscape increasingly dominated by targeted therapies (proteasome inhibitors, IMiDs, monoclonal antibodies) and newer mechanisms. As an oral alkylating agent, it offers practical administration advantages but lacks the specificity of contemporary approaches. The program's apparent stagnation suggests Ultragenyx may have concluded that melphalan monotherapy does not offer sufficient efficacy or safety advantages over existing standards of care in amyloidosis.

Future Catalysts: Disclosure of Phase 2 results would clarify the program's status and rationale for non-advancement. Potential catalysts include: (1) publication of trial data in peer-reviewed literature; (2) announcement of program discontinuation or strategic refocus; (3) partnership or licensing announcements; (4) initiation of combination therapy trials. None of these catalysts are evident in current available facts.

Expected Milestones: Expected next milestone not yet disclosed. Given the 16-year gap since the last recorded milestone, active development appears unlikely unless Ultragenyx has recently re-initiated the program without public disclosure.

• Phase 2 completion (June 2008) represents the final disclosed development milestone
• No Phase 3 initiation, regulatory filing, or approval announced
• Program status (active, discontinued, on hold) not yet disclosed
• Clinical trial results from NCT00017680 not yet published in available facts